Crexendo and NUSO Partner to Deliver Global Cloud Communications Capabilities
23.10.2025 16:15:00 EEST | Business Wire | Press release
NUSO, a leading provider of cloud communications service delivery, today announced it has been chosen by Crexendo®, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communication as a service (UCaaS) offerings, including voice, video, contact center, and managed IT services tailored to businesses of all sizes, to be a preferred carrier for the Crexendo cloud communications platform. The expanded partnership allows Crexendo platform licensees to offer cloud communications capabilities over NUSO’s global delivery network, unlocking new revenue opportunities for service providers. With NUSO’s carrier footprint in more than 40 countries, the Crexendo platform now offers global service delivery with industry-leading call quality, uptime, and emergency calling compliance. Platform providers can now offer global service delivery to over 6 million end users worldwide who rely on Crexendo’s Netsapiens platform.
"Crexendo has long been an award-winning, trusted cloud communications platform provider, and our partnership with NUSO further extends our platform’s features on a global scale,” said Jeff Korn, Crexendo Chairman and CEO. “We appreciate NUSO’s service expansion and increased investment in the NetSapiens Platform in the US and Europe. In addition, our platform licensees now have new opportunities to generate revenue by offering these new global capabilities to their end-user customers. I’m very excited about Crexendo’s partnership with NUSO, and their Event Sponsorship of our User Group Meeting in Miami Beach next week. This partnership is yet another example of the growth and advancements in our platform that we continue to make for our valued service providers and their customers.”
“Crexendo’s platform has long set the standard for innovation and partner enablement in cloud communications,” said Matt Siemens, CEO of NUSO. “We’re proud to extend that vision globally through our carrier network and platform capabilities. Together, we’re giving service providers the reach, reliability, and compliance they need to deliver world-class communications anywhere their customers do business.”
Additional information on the NUSO partnership will be shared at Crexendo’s upcoming NetSapiens Platform User Group Meeting (UGM) to be held in Miami Beach, Florida, from October 27 through October 30, where the industry's leading service providers and technology partners come together to shape the future of cloud communications. NUSO is an Event Sponsor of Crexendo’s 2025 UGM.
About NUSO
NUSO is a global cloud communications provider that brings together AI powered voice, messaging, collaboration, contact center, and carrier-grade infrastructure in one secure platform. NUSO helps partners and enterprises scale faster, meet compliance demands, and deliver better customer experiences. With NUSO, organizations move beyond call routing to orchestrating the outcomes that matter. NUSO is ISO 27001:2022 certified and operates across the United States, Canada, Latin America, UK, and EMEA. Learn more at www.nuso.cloud.
About Crexendo
Crexendo, Inc. is an award-winning software technology company that is a premier provider of cloud communication platform and services, video collaboration and managed IT services tailored to businesses of all sizes. Our solutions currently support over six million end users globally, through our extensive global network of over 235 cloud communication platform software subscribers and our direct retail offering. For more information, please visit www.crexendo.com.
Safe Harbor Statement
This press release contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor'' for such forward-looking statements. The words, "believe,'' "expect,'' "anticipate,'' "estimate," "will'' and other similar statements of expectation identify forward-looking statements. Specific forward-looking statements in this press release include information about Crexendo (i) allowing platform licensees to offer cloud communications capabilities over NUSO’s global delivery network; (ii) unlocking new revenue opportunities for service providers; (iii) platform offering global service delivery with industry-leading call quality, uptime, and emergency calling compliance; (iv) platform providers offering global service delivery to over 6 million end users worldwide who rely on Crexendo’s platform; (v) partnership with NUSO further extending its platform’s features on a global scale; (vi) platform licensees having new opportunities to generate revenue by offering these new global capabilities to their end-user customers; (vii) partnership being yet another example of the advancements in our platform we continue to make for our valued service providers and their customers; (viii) setting the standard for innovation and partner enablement in cloud communications; (ix) extending that vision globally through NUSO’s carrier network and platform capabilities; (x) giving service providers the reach, reliability, and compliance they need to deliver world-class communications anywhere their customers do business; (xi) sharing information on the NUSO partnership at Crexendo’s upcoming NetSapiens Platform User Group Meeting (UGM).
For a more detailed discussion of risk factors that may affect Crexendo's operations and results, please refer to the company's Form 10-K for the year ended December 31, 2024, and Form 10-Qs as filed with the SEC. These forward-looking statements speak only as of the date on which such statements are made, and the company undertakes no obligation to update such forward-looking statements, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251023910688/en/
Contacts
NUSO Contact:
Colleen Sheley
VP of Marketing, NUSO
marketing@nuso.cloud
Crexendo Contact:
Doug Gaylor
President and Chief Operating Officer
dgaylor@crexendo.com
602-732-7990
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 08:03:00 EEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom